Vistagen Therapeutics Inc

Vistagen Therapeutics beats Q3 earnings and revenue expectations, expands PALISADE‑4 trial with $61.8 M, driving its intranasal CNS therapy pipeline forward.

Vistagen Therapeutics faces a financial crossroads: no pipeline progress, steep stock volatility, negative earnings, and low market value raise investor doubts about its future viability and profitability in biotech.

Vistagen Therapeutics’ stock has experienced fluctuations, reaching a 52-week high of $4.21 and a 52-week low of $1.90, amidst its focus on developing treatments for central nervous system disorders.

VistaGen Therapeutics, a clinical-stage biopharmaceutical company, is set to release its earnings report on June 17, 2025, with analysts projecting a loss of -$0.497 per share and a 215% increase in quarterly revenue.

Vistagen Therapeutics, a clinical-stage biopharmaceutical company, is pioneering treatments for central nervous system (CNS) disorders, offering hope for patients and healthcare professionals worldwide.

Vistagen Therapeutics is a clinical-stage biopharmaceutical company pioneering treatments for central nervous system (CNS) disorders, with a focus on transforming the lives of patients affected by conditions like Alzheimer’s and Parkinson’s disease.

Vistagen Therapeutics, a clinical-stage biopharmaceutical company, is pioneering innovative treatments for central nervous system disorders, offering hope to patients and investors alike in the rapidly evolving biotech landscape.